Resumo (PT):
Introduction: Angiotensin II (AT-II) is an endogenous peptide whose effects are mediated
by two types of receptors, AT1 and AT2. AT1 receptors are responsible for the vasoconstrictor,
positive inotropic and growth promoting properties of AT-II, while AT2
receptors have been linked to vasodilator and anti-mitogenic properties. In this study we
investigated the effects of selective AT2 receptor stimulation on myocardial contractility,
which are not yet known. Methods: Effects of selective AT2 receptor activation were
evaluated in rabbit right papillary muscles (n=35) by adding, to the superfusing solution
(Krebs-Ringer; 1.8mM CaCl2; 35ºC), increasing doses of AT-II (10-8, 10-7, 10-6, 10-5 M) in
the presence of a selective AT1 receptor antagonist (ZD7155, 10-6 M). Effects of selective AT2 receptor activation were evaluated in the absence (n=12) and in the presence of
NG-nitro-L-Arginine (L-NA; 3*10-5 M; n=9) or Indomethacin (INDO; 10-3 M; n=7), as well
as, in muscles without endocardial endothelium (EE; n=7). Calculated parameters: active
tension (AT), peak rates of tension rise and decline (dT/dtmax and dT/dtmin, respectively),
peak shortening (PS) and peak rate of shortening (dL/dtmax). Results are presented
as mean±SEM in % of baseline (p<0.05). Results: Selective AT2 stimulation
induced a dose-dependent negative inotropic effect, decreasing, at 10-5 M of AT-II,
29.3±7.7% AT, 26.1±7.0% dT/dtmax, 27.9±7.5% dT/dtmin, 30.7±9.3% PS and
22.0±5.7% dL/dtmax. This effect was not influenced by L-NA (10-5 M of AT-II decreased
32.5±10.2% AT, 25.7±7.8% dT/dtmax, 26.7±8.6 dT/dtmin, 16.90±7.1 dL/dtmax) or INDO
(10-5 M of AT-II decreased 34.4±7.1% AT, 27.9±6.1 dT/dtmax, 33.2±7.9 dT/dtmin,
20.2±5.0 dL/dtmax, 36.6±10.2 dL/dtmin, 25.3±7.1 PS), but was completely abolished
after selective removal of the EE. Conclusions: Selective AT2 stimulation induces a negative
inotropic effect, which is modulated by the EE, but not mediated by NO or prostaglandins.
Such findings might help to better understand the therapeutic effects of selective
AT1 antagonists, which are being increasingly used in for treating cardiovascular diseases
Language:
English
Type (Professor's evaluation):
Scientific
Notes:
54th Annual Scientific Session of the American-College-of-Cardiology, published in Journal, American College of Cardiology. 2004; 43(Suppl.A):492A-493A.